TCA
PFE icon

Transcend Capital Advisors’s Pfizer PFE Stock Holding History

Transcend Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$619K Buy
25,696
+6,754
+36% +$177K 0.04% 384
2026
Q1 		$532K Sell
18,942
-7,434
-28% -$198K 0.04% 367
2025
Q4 		$657K Sell
26,376
-21,315
-45% -$538K 0.05% 314
2025
Q3 		$1.22M Sell
47,691
-9,845
-17% -$243K 0.09% 218
2025
Q2 		$1.39M Sell
57,536
-66,050
-53% -$1.54M 0.11% 173
2025
Q1 		$3.13M Sell
123,586
-28,283
-19% -$740K 0.22% 107
2024
Q4 		$4.03M Sell
151,869
-8,115
-5% -$220K 0.29% 81
2024
Q3 		$4.63M Buy
159,984
+5,216
+3% +$152K 0.31% 77
2024
Q2 		$4.33M Buy
154,768
+1,245
+0.8% +$34.3K 0.31% 71
2024
Q1 		$4.26M Buy
153,523
+32,246
+27% +$895K 0.34% 68
2023
Q4 		$3.49M Buy
121,277
+57,988
+92% +$1.75M 0.31% 75
2023
Q3 		$2.1M Sell
63,289
-6,157
-9% -$218K 0.2% 117
2023
Q2 		$2.55M Buy
69,446
+1,834
+3% +$71.4K 0.24% 98
2023
Q1 		$2.76M Sell
67,612
-1,871
-3% -$80.8K 0.29% 87
2022
Q4 		$3.56M Sell
69,483
-6,196
-8% -$297K 0.39% 58
2022
Q3 		$3.31M Sell
75,679
-1,063
-1% -$51.7K 0.37% 61
2022
Q2 		$4.02M Buy
76,742
+490
+0.6% +$25K 0.42% 52
2022
Q1 		$3.95M Buy
76,252
+6,061
+9% +$314K 0.35% 66
2021
Q4 		$4.14M Buy
70,191
+2,038
+3% +$101K 0.37% 68
2021
Q3 		$2.97M Buy
68,153
+628
+0.9% +$27.8K 0.27% 98
2021
Q2 		$2.65M Buy
67,525
+4,047
+6% +$157K 0.38% 69
2021
Q1 		$2.3M Buy
63,478
+748
+1% +$26.6K 0.28% 93
2020
Q4 		$2.31M Sell
62,730
-51,827
-45% -$1.9M 0.3% 89
2020
Q3 		$3.99M Buy
114,557
+27,771
+32% +$974K 0.73% 28
2020
Q2 		$2.69M Sell
86,786
-7,633
-8% -$259K 0.88% 37
2020
Q1 		$2.93M Buy
94,419
+780
+0.8% +$26.6K 0.88% 27
2019
Q4 		$3.48M Buy
+93,639
New +$3.34M 0.94% 23

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Transcend Capital Advisors's PFE Position: Q2 2026 in Review

Transcend Capital Advisors increased its Pfizer (PFE) stake by 36% in Q2 2026, buying an estimated $177K and bringing the position to 25,696 shares worth $619K. The position accounts for 0.04% of the portfolio, ranked #384.

Transcend Capital Advisors first reported a position in PFE in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.63M in Q3 2024. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Transcend Capital Advisors held 25,696 shares of Pfizer worth $619K as of Q2 2026.
  • Transcend Capital Advisors bought 6,754 Pfizer shares in Q2 2026, an estimated $177K.
  • Pfizer made up 0.04% of Transcend Capital Advisors's portfolio in Q2 2026, its #384 holding.
  • Transcend Capital Advisors first reported a position in Pfizer in Q4 2019 and has held it in 27 quarters since.
  • Transcend Capital Advisors's Pfizer position peaked at $4.63M in Q3 2024.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.